Stockscreener 앱 받기
0.1861
17.65%
-0.0399
시간 외 거래:
.19
0.0039
+2.10%
전일 마감가:
$0.226
열려 있는:
$0.1975
하루 거래량:
10.69M
Relative Volume:
3.64
시가총액:
$2.65M
수익:
$212.10K
순이익/손실:
$-40.19M
주가수익비율:
-0.000495
EPS:
-376.0263
순현금흐름:
$-13.92M
1주 성능:
-46.55%
1개월 성능:
-45.09%
6개월 성능:
-99.69%
1년 성능:
-99.90%
1일 변동 폭
$0.185
$0.2099
1주일 범위
$0.185
$0.346
52주 변동 폭
$0.185
$338.80
애디텍스트 Stock (ADTX) Company Profile
명칭
Aditxt Inc
전화
909-488-0844
주소
737 N. FIFTH STREET, SUITE 200, RICHMOND
ADTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADTX
Aditxt Inc
|
0.1861 | 2.65M | 212.10K | -40.19M | -13.92M | -5,313.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
애디텍스트 주식(ADTX)의 최신 뉴스
Aditx Therapeutics stock hits 52-week low at $0.31 - Investing.com
Aditxt, Inc. (NASDAQ:ADTX) Sees Large Decrease in Short Interest - Defense World
Aditxt Advances ADI-100 Therapy to Human Trials - TipRanks
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials - Quantisnow
Evofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits - Quantisnow
Evofem Biosciences Announces Financial Results for the Third Qua - GuruFocus.com
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - Marketscreener.com
Aditxt extends merger agreement end date to January 2025 - Investing.com
Aditxt extends merger agreement end date to January 2025 By Investing.com - Investing.com UK
Appili Therapeutics Moves Forward with Aditxt Acquisition - TipRanks
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc. - The Manila Times
Evofem Secures Investor Support for Proposed Merger through Voti - GuruFocus.com
Aditxt Inc. (ADTX) Quarterly 10-Q Report - Quartz
Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ADTX stock plunges to 52-week low of $0.32 amid market challenges - Investing.com Canada
Evofem Cuts Q3 Operating Loss 31%, Acquires SOLOSEC Rights Despite Sales Dip | ADTX Stock News - StockTitan
Enviri Corp (NYSE: NVRI): Blank Check On Growth? - Stocks Register
Appili Therapeutics shareholders vote in favor of Aditxt transaction - TipRanks
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 - The Manila Times
Aditxt, Inc. (NASDAQ:ADTX) Short Interest Update - Defense World
Aditxt suspends equity financing amid acquisition strategy - Investing.com
Aditxt suspends equity financing amid acquisition strategy By Investing.com - Investing.com UK
ADTX stock plunges to 52-week low, touches $0.42 - Investing.com India
ADTX stock plunges to 52-week low, touches $0.42 By Investing.com - Investing.com UK
Aditxt Secures Overwhelming Shareholder Approval for Appili Therapeutics Acquisition | ADTX Stock News - StockTitan
Appili Therapeutics Announces Results of Special Meeting of Shareholders - The Manila Times
Appili Shareholders Approve Acquisition by Aditxt - TipRanks
Appili Therapeutics Announces Results of Special Meeting of Shareholders - GlobeNewswire Inc.
Aditxt announces Evofem secures voting agreements with investors for merger - TipRanks
Evofem Biosciences Gains Support for Aditxt Merger - TipRanks
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem - Quantisnow
Evofem Secures Investor Support for Proposed Merger through Voting Agreements - StreetInsider.com
Evofem Secures Key Merger Support as Aditxt Completes $5M Investment Commitment | ADTX Stock News - StockTitan
Aditxt Discloses Information About Compliance with Nasdaq Listing Requirements in 8-K Filing** - Defense World
Aditxt, Inc. Focuses on Growth Amid Nasdaq Compliance - TipRanks
A Biotech Empire Rises in Inland Southern California - Site Selection Magazine
Aditxt receives positive FDA feedback on ATI-1801 development By Investing.com - Investing.com Australia
ADTXAditxt, Inc. Latest Stock News & Market Updates - StockTitan
Aditxt receives positive FDA feedback on ATI-1801 development - Investing.com India
Evofem Biosciences enters agreements amid merger plans - Investing.com
Evofem Biosciences Faces Merger and Credit Challenges - TipRanks
Evofem Biosciences enters agreements amid merger plans By Investing.com - Investing.com UK
ADTX stock plunges to 52-week low of $0.53 amid market challenges - Investing.com
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - StockTitan
Appili Therapeutics’ FDA Alignment and Aditxt Acquisition - TipRanks
Appili Therapeutics announces FDA alignment on ATI-1801 NDA requirements - TipRanks
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - The Manila Times
Aditxt Enters Major Investment Agreement with Evofem - TipRanks
Aditxt appoints Sylvia Hermina to board By Investing.com - Investing.com Canada
Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives - Quantisnow
Aditxt appoints Sylvia Hermina to board - Investing.com
애디텍스트 (ADTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
애디텍스트 주식 (ADTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Oct 16 '24 |
Sale |
1.17 |
25,534 |
29,875 |
0 |
2.88%
2.65%
자본화:
|
볼륨(24시간):